Scientists dive deep into Epcoritamab's effects on blood cancers
NCT ID NCT06676033
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This study looks at blood, bone marrow, and lymph node samples from people with chronic lymphocytic leukemia (CLL) or Richter syndrome who are already receiving epcoritamab in another trial. The goal is to learn how the drug changes immune cells and cancer cells over time. Only 5 participants are being invited to join. This is a correlative study, meaning it does not test a new treatment but rather gathers information to improve future therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RICHTER SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.